Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of lapatinib in combination with
chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing
breast cancer whose disease has progressed during or within 12 months after completion of
trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.